Baseline patient and disease characteristics among randomized patients by CRP level at Week 104. For the variables, n/N refers to number of patients with that data/total number of patients.
| Baseline Variables | CRP, mg/dl, at < 0.5 | Week 104 ≥ 0.5 |
|---|---|---|
| Age, yrs, N | 231 | 45 |
| Mean ± SD | 39.0 ± 12.24 | 39.8 ± 11.85 |
| p | 0.5928 | |
| Male, % (n/N) | 74.5 (172/231) | 66.7 (30/45) |
| p | 0.2804 | |
| BASDAI, 0–10, N | 231 | 45 |
| Mean ± SD | 6.5 ± 1.44 | 6.8 ± 1.72 |
| p | 0.1721 | |
| BASFI, 0–10, N | 229 | 45 |
| Mean ± SD | 4.7 ± 2.36 | 6.8 ± 1.98 |
| p | < 0.0001 | |
| BASMI, 0–10, N | 231 | 45 |
| Mean ± SD | 3.3 ± 2.02 | 4.8 ± 2.38 |
| p | < 0.0001 | |
| CRP, mg/dl, N | 231 | 45 |
| Mean ± SD | 1.6 ± 1.86 | 3.1 ± 2.44 |
| p | < 0.0001 | |
| AS diagnosis duration, yrs, N | 231 | 45 |
| Mean ± SD | 8.5 ± 8.62 | 10.5 ± 9.75 |
| p | 0.2298 | |
| HLA-B27+, % (n/N) | 86.6 (200/231) | 86.7 (39/45) |
| p | 0.9876 | |
| PtGA of disease, 0–10, N | 230 | 45 |
| Mean ± SD | 6.7 ± 1.75 | 7.5 ± 1.96 |
| p | 0.0063 | |
| Yrs since symptoms of SpA first occurred, n | 231 | 45 |
| Mean ± SD | 12.5 ± 10.41 | 17.8 ± 11.75 |
| p | 0.0023 | |
| mSASSS score, 0–72, N | 236 | 47 |
| Mean ± SD | 12.5 ± 16.69 | 20.8 ± 23.51 |
| p | 0.0028 |
CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; AS: ankylosing spondylitis; PtGA: patient’s global assessment; SpA: spondyloarthritis; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score.